🔎 Trials Near Me

Akèy › Kansè Poumon ki pa ti selil › Washington › Vancouver

Etid klinik pou Kansè Poumon ki pa ti selil nan Vancouver, WA

9 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Vancouver (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Ap rekriteFaz 3
  • Compass Oncology, Vancouver
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06765109

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Ap rekriteFaz 3
  • Northwest Cancer Specialists PC, Vancouver
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06890598

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Ap rekriteFaz 3
  • Clinical Study Site, Vancouver
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06767514

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Ap rekriteFaz 2/3
  • USOR - Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center, Vancouver
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04613596

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Ap rekriteFaz 3
  • USO - Northwest Cancer Specialists, Vancouver
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06119581

MYLUNG Consortium Part 3: Observational Study

Ap rekriteEtid obsèvasyon
  • Northwest Cancer Specialists, P.C., Vancouver
Laj 18 ak plis · Tout sèks · Mizajou May 18, 2026 · NCT05885698

Etid Kansè Poumon ki pa ti selil nan lòt vil

Lòt etid nan Vancouver

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.